Objective: The objective of this study was to quantify hormones that regulate energy and glucose homeostasis to establish possible mechanisms for the greater efficacy of Roux-en-Y gastric bypass (RYGB) compared with laparoscopic adjustable gastric banding (LAGB) in achieving weight loss and improved insulin sensitivity. Design: Longitudinal study of patients undergoing LAGB (n ¼ 15) and RYGB (n ¼ 28) who were studied before surgery and at 2, 12, 26 and 52 weeks afterwards. Measurements: Fasting blood samples were drawn at each visit. Postprandial blood samples were also obtained before surgery and at 26 and 52 weeks. Samples were assayed for peptide YY (PYY), ghrelin, glucagon-like peptide-1 (GLP-1), glucose, insulin, leptin, thyrotropic hormone, free T 4 and free T 3 . Results: At 1 year there was greater weight loss in RYGB compared with LAGB patients (30 vs 15%), but final body mass index was similar (34 vs 33 kg m À2 ). At week 52, area under the curve (AUC) for PYY in RYGB subjects was greater than LAGB (Po0.01). GLP-1 levels at 30 min after meal were threefold greater after RYGB compared with LAGB (Po0.001). Conversely, ghrelin AUC increased after LAGB at week 52 (Po0.05) but tended to decrease after RYGB. Fasting glucose, insulin, and leptin and homeostasis model of assessment (HOMA-IR) decreased in both groups over time but were significantly lower at week 52 after RYGB compared with LAGB. The change in leptin correlated significantly with weight loss in LAGB (r ¼ 0.86) and RYGB (r ¼ 0.77), however, HOMA-IR correlated significantly with weight loss only in LAGB (r ¼ 0.78), and not RYGB (r ¼ 0.15). There was a significant decrease in free T 3 (Po0.01) after RYGB. Conclusions: Differences in levels of gut hormones may play a role in promoting greater weight loss and insulin sensitivity after RYGB compared with LAGB, however, weight loss may be limited by decreases in free T 3 and leptin.
Introduction
The absence of effective pharmacotherapy for morbidly obese individuals, together with the rise in the prevalence of extreme obesity (BMI X40 kg m À2 ) have resulted in a surge in the number of surgical procedures performed for weight loss. 1, 2 The average reduction in body weight is B28% after laparoscopic adjustable gastric banding (LAGB) and 40% after Roux-en-Y gastric bypass (RYGB) and metabolic benefits such as remission of type 2 diabetes occurs in 48 and 84% in LAGB and RYGB patients, respectively. 3, 4 Both LAGB and RYGB produce weight loss by restricting nutrient flow; the former, through an adjustable band placed around the upper stomach, and the latter by surgical division of the stomach to create a small proximal pouch. RYGB also causes a redirection of nutrient flow from the upper portion of the stomach directly into the mid-to distal jejunum that may cause micronutrient deficiencies, but malabsorption of macronutrients does not typically occur. Recently, there has been greater recognition that the modality of weight loss, not just the degree, may have independent effects on neurohormonal regulators of energy balance and glucose homeostasis. 5, 6 Changes in hormone secretion may then contribute to the efficacy of the particular procedure in producing long-term weight loss and improvement in obesity-related co-morbidities.
A panoply of hormones is secreted from the gastrointestinal tract that contributes to the regulation of energy balance and glucose homeostasis through interaction with peripheral tissues and communication with the central nervous system as part of the 'gut-brain axis'. 7 The gut hormones of interest in this report are peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and ghrelin. Secretion of PYY and GLP-1 occurs shortly after food intake from L cells that are located predominantly along the distal small bowel and colon. Both peptides decrease appetite, increase satiety, slow gut motility and improve insulin sensitivity. 7 As part of the 'enteroinsular axis,' GLP-1 also functions as an incretin to potentiate glucose-stimulated insulin release. In contrast, ghrelin stimulates appetite, increases food intake and gut motility and decreases insulin sensitivity. 8 Secretion of ghrelin from A cells in the oxyntic glands of the stomach fundus is suppressed after a meal and is downregulated in obese individuals. Weight loss by caloric restriction is associated with an increase in circulating concentrations of ghrelin. 9 In earlier cross-sectional studies, we have shown that circulating levels of several gut hormones differ in patients who had undergone LAGB compared with RYGB. 10, 11 The most striking difference between procedures was an exaggerated postprandial increase in PYY, GLP-1 and insulin concentrations in the RYGB group. Fasting ghrelin levels were not different, but the large inter-individual variability and absence of pre-operative data make interpretation of the ghrelin data difficult. A number of other studies have characterized changes in gut hormones after bariatric surgery but prospective studies of a side-by-side comparison of fasting and postprandial hormonal changes after LAGB and RYGB are lacking. 12 Given the therapeutic implications that may arise from an understanding of how different modalities of weight loss affect gut hormone secretion and glucose homeostasis, we performed a prospective study of individuals undergoing LAGB and RYGB. Levels of gut peptides before surgery and at 2, 12, 26 and 52 weeks after surgery were assessed in addition to insulin, leptin and thyroid hormones that also influence metabolism.
Materials and methods

Study subjects
Subjects older than 21 years of age who were scheduled to undergo LAGB (n ¼ 15; 11F/4M) or RYGB (n ¼ 28; 24F/4M) were recruited. Individuals who reported the use of weight loss medications within 90 days before enrollment were excluded from the study. Criterion for a diagnosis of type 2 diabetes mellitus was based on a fasting glucose X126 mg per 100 ml in individuals not taking diabetes medications. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. The study was approved by the Columbia University Institutional Review Board and written informed consent was obtained from all subjects.
Surgery
The choice of bariatric procedure was based on the preference of surgeon and patient. The surgical procedure for the LAGB consisted of placement of an adjustable silastic band (Lap-Band, INAMED Health, Santa Barbara, CA, USA) around the proximal stomach attached by tubing to a port sutured to the anterior rectus fascia. The inner diameter of the band, and thereby the size of the opening through which nutrients must pass, was adjusted post-surgically through the access port by removal or addition of saline within the band system. The surgical procedure for RYGB consisted of creation of a 15-30 ml pouch that was divided from the proximal lesser curvature of the stomach and excluded the fundus. The pouch was anastomosed to a Roux limb of jejunum created by division of the jejunum 50-100 cm distal to the ligament of Treitz and anastomosing the afferent biliopancreatic limb to the jejunum 100-150 cm distally. Division of the vagus nerve and its branches was avoided.
Protocol
Subjects were studied at a mean of 5.8 weeks before surgery, and at 2, 12, 26 and 52 weeks after surgery. Body weight was measured and fasting venous blood samples were drawn at all visits. A liquid meal challenge (Optifast, Novartis, Minneapolis, MN, USA; 474 ml, 320 kcal, 50% carbohydrate, 35% protein and 15% fat) consumed within a 15 min period was administered at the pre-operative visit and at 26 and 52 weeks after the surgical procedure. The choice of the meal challenge was based on our earlier studies showing that the macronutrient content and volume load does not elicit dumping syndrome or abdominal discomfort in post-surgery patients. 11, 13 Venous blood was drawn in the fasted state and 30, 60, 90 and 120 min after meal.
Hormone assays
Plasma hormone measurements were performed on blood samples collected in EDTA tubes that were centrifuged for 15 min at 4 1C and stored at À80 1C until assayed in duplicate. Plasma leptin and total ghrelin (acyl-and desacyl forms) were measured as described earlier. 13 Total plasma levels of PYY were measured using a commercial enzyme-linked immunosorbent assay (Diagnostic Systems Laboratories, Webster, TX, USA) that measures PYY and PYY . The lower limit of detection was 12 pg ml À1 and the coefficients of variation were 10.1% within and 10.3% between assays. Owing to discontinued production of the DSL assay during this study, B15% of samples were assayed for PYY using an enzyme-linked immunosorbent assay from LINCO Research (St Charles, MO, USA). There was significant correlation between assays (r ¼ 0.9, Po0.001), however, absolute values were lower in the LINCO assay. The following equation was found by an ordinary least squares solution to calculate comparable DSL value: À58.3 þ 2.8(LINCO value). The number of subjects from whom test meal samples were analyzed with the LINCO PYY assay were as follows: for LAGB, 1, 1, and 6 subjects for weeks 0, 26, and 52, respectively; for RYGB, 3, 5, and 7 subjects for weeks 0, 26, and 52, respectively. Total GLP-1 was measured by RIA (LINCO). Owing to the large number of samples and requirement of alcohol extraction, only plasma collected pre-meal and at 30 min was analyzed. Serum insulin (lower limit of detection of 2 mIU ml À1 ), free T 3 , free T 4 and thyrotropic hormone were measured with the Immulite Analyzer (Siemens, Los Angeles, CA, USA). Plasma glucose was measured by the hexokinase method.
Statistical analysis SAS version 9.1software (Cary, NC, USA) was used for statistical analysis. Insulin resistance was calculated using the homeostasis model of assessment (HOMA-IR): fasting insulin in microunits per ml Â fasting glucose in mmoles per liter/22.5. 14 Differences in the distribution of continuous variables at baseline were tested with Student's independent t-test. Longitudinal changes from baseline were tested with linear mixed models with fixed effects for surgical group, week and group by week interaction with an autoregressive 1 covariance structure for the repeated measures. Postprandial excursion differences between surgical groups were assessed with linear mixed models with fixed effect of group, week, group by week interaction, week by sample time interaction and group by week by sample time interaction with a spatial power covariance structure for repeated measures. The association between variables was estimated using Pearson's correlations. All tests were two-tailed, with P-values o0.05 considered statistically significant. No adjustment of the critical value of the test statistic was made for the separate tests of different hormones or for HOMA-IR, although a significant F-test was required for the fixed effect for post hoc comparisons of between group differences at specific times, or within-group differences between times using 95% confidence intervals and the model estimated means and standard errors. The area under the curve (AUC) was calculated using the trapezoidal rule. Statistical model estimated means and standard errors are presented.
Results
Baseline characteristics and weight change
Age was similar between groups (LAGB, 47. 1±2.5; RYGB, 45.0 ± 2.0 years), whereas body weight (112 ± 5 vs 128 ± 5 kg; P ¼ 0.056) and BMI (41 ± 1 vs 48 ± 1 kg m À2 ; Po0.001) were less in LAGB compared with RYGB. Changes in BMI and body weight are depicted in Figure 1 . At 1 year, 13/15 LAGB and 25/28 RYGB subjects were available for follow-up measurements. Percentage decrease in total body weight at 1 year was twofold greater in RYGB compared with LAGB (À15 ± 2.3 vs À30 ± 1.2%; Po0.001). There was a wide variation in the range of weight change with both procedures (LAGB, þ 5 to À27; RYGB, À18 to À41%). At 1 year, both groups were of similar weight (LAGB, 94 ± 4.5; RYGB 88±3.6 kg; P ¼ 0.221) and BMI (LAGB, 34±1.1; RYGB, 33±1.0 kg m À2 ; P ¼ 0.438).
Peptide YY
Fasting levels of PYY were not significantly different between groups at any time point (Table 1 ). There was a progressive increase in fasting PYY in the RYGB group such that at week 52 levels were significantly greater than baseline (P ¼ 0.014). The most striking differences in PYY levels were noted postmeal in RYGB subjects. At 26 and 52 weeks, PYY levels at Hormone changes after bariatric surgery J Korner et al 30 min were B3.5-fold greater than levels before surgery and were significantly greater than in LAGB subjects at the same time points (Figure 2 , Po0.001). There was a corresponding threefold increase in AUC for PYY in the RYGB group at week 26 (Po0.001) and a continued increase in PYY levels such that AUC at week 52 was significantly greater than at week 26 (P ¼ 0.025). AUC in the LAGB subjects was also increased after surgery but the difference was statistically significant only at week 26 (P ¼ 0.003). The non-significant increase in AUC for PYY at week 52 may be because of a change in assay (see Materials and methods). PYY did not correlate with percentage weight loss in either group.
Ghrelin
Absolute levels of fasting ghrelin in LAGB subjects at week 52 did not increase significantly compared with baseline ( Table 1 , P ¼ 0.073), although the change in ghrelin was significant (43 ± 12%, P ¼ 0.001), as was the increase in AUC (Figure 2 , P ¼ 0.044). Conversely, there was a downward trend in fasting ghrelin levels in RYGB, but the difference in fasting values at week 52 compared with baseline was not statistically significant (P ¼ 0.422). The degree of suppression of ghrelin levels post-meal did not differ significantly presurgery to week 52 in either the LAGB (16% ± 3.5 vs 19% ± 3.2) or the RYGB (21% ± 3.4 vs 22% ± 1.8) and did not differ between groups. Changes in fasting ghrelin or AUC did not correlate with percentage weight loss in either group.
Glucose, insulin and HOMA-IR Subjects with type 2 diabetes (2 LAGB and 6 RYGB) at baseline were excluded from analyses of glucose, insulin and HOMA-IR. Fasting glucose, insulin and HOMA-IR decreased to a greater extent after RYGB (Table 1) . Postprandial insulin levels peaked at 30 min and were not different between LAGB and RYGB, however, there was a more rapid decrease in the RYGB group such that insulin levels at 60 min were significantly lower at week 26 (P ¼ 0.002) and week 52 (P ¼ 0.016) compared with the same time points in the LAGB subjects ( Figure 3 ). Although baseline HOMA-IR levels were not predictive of the amount of weight loss at 1 year (r ¼ À0.22, P ¼ 0.5), HOMA-IR correlated significantly with percentage weight loss at week 12 (r ¼ 0.64, P ¼ 0.024) and week 52 (r ¼ 0.78, P ¼ 0.005), (Figure 3 ). Significant correlation of HOMA-IR and percentage weight loss was not observed in RYGB subjects at week 12 when the range of loss was comparable to LAGB at 1 year (r ¼ 0.21; P ¼ 0.37), or at week 52 (r ¼ 0.15, P ¼ 0.56) (Figure 3 ).
Glucagon-like peptide-1
To more fully understand the pattern of insulin secretion, levels of the incretin hormone, GLP-1, were examined. Fasting levels of GLP-1 did not change significantly over time in either group (Table 1) . In LAGB patients, the postprandial rise of GLP-1 measured at 30 min did not change after surgery (Figure 4 ). In contrast, postprandial GLP-1 levels after RYGB were significantly greater (Po0.001) compared with 30 min values before surgery and threefold higher compared the same time points after LAGB (Po0.001).
Leptin
Fasting leptin levels did not differ at baseline between groups (Table 1 ). There was a significant decrease at week 2 in LAGB subjects (Po0.001), but levels did not decrease further despite continued weight loss. Leptin levels at week 2 were also significantly decreased in RYGB subjects (Po0.001). The percentage change from baseline after RYGB ( Figure 5 ) continued to decrease from weeks 2 to 12 (Po0.001) and weeks 12 to 26 (P ¼ 0.019), showing stabilization from weeks 26 to 52 (P ¼ 0.294). The percentage change in leptin correlated with percentage weight loss at week 52 in LAGB (r ¼ 0.86, Po0.001) and RYGB (r ¼ 0.77, Po0.001) ( Figure 5 ).
Thyroid function
Free T 4 , free T 3 and thyrotropic hormone did not change significantly over time in the LAGB group (Table 2) , 
Discussion
In this report, we show that LAGB and RYGB have different effects on fasting and postprandial concentrations of several hormones that have been shown in animal and human studies to modulate appetite, food intake, energy partitioning, energy expenditure and insulin sensitivity ( Table 3) . As discussed below, some of these changes were mostly related to weight loss regardless of the type of surgery, yet some were mostly because of the surgical intervention itself. 
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Several prospective studies of RYGB have also shown an increase in postprandial plasma levels of PYY and/or GLP-1. 12 This increase has been reported to occur as early as 2 days after bypass suggesting that the exaggerated response is secondary to the intervention per se and not to weight loss and is likely related to more rapid delivery of glucose to the distal small intestine. 15 We have also shown that over time after RYGB, there was a further increase in both fasting and postprandial PYY levels that may reflect adaptive changes within the gut. Biliopancreatic diversion in rats is associated Hormone changes after bariatric surgery J Korner et al with increased GLP-1 and PYY levels together with hypertrophy and increased mitoses within crypts of the distal small intestine. 16 Similarly, hyperplasia of enteroglucagoncontaining cells has been shown in the ileum in humans after jejuno-ileal bypass. 17 Consistent with other reports, [18] [19] [20] we did not detect an increase in fasting GLP-1. Others have shown that glucose tolerance and obesity impair the incretin effect independently of one another 21 and that a diet-induced weight loss of 14.8% increases the GLP-1 response curve over a 180 min period. 22 In our study, we did not observe an increase in postprandial GLP-1 levels in LAGB patients after a similar amount of weight loss, however, a single postprandial measurement at 30 min may not have been adequate to detect subtle changes. Unfortunately, owing to the limitation in sample volume we were unable to obtain GLP-1 measurements for the entire postprandial period. It is unlikely, although, that major changes were missed; given that in an earlier cross-sectional study we showed that at 60 min post-meal, there still is a significant difference in GLP-1 levels between LAGB and RYGB subjects. 10 Several studies have shown that PYY and GLP-1 levels may be associated with weight loss after RYGB. AUC of PYY was shown to increase at a mean of 32.5 months in subjects in the upper quartile of weight loss relative to the evaluation performed at 52 weeks after surgery. 23 In a cross-sectional analysis of patients who had undergone bypass, AUC of PYY and GLP-1 was greater in 'good' compared with 'poor' responders. 24 Although these associations do not prove causality, inhibition of gut hormone release by administration of somatostatin increased appetite and food intake in bypass but not in band subjects, suggesting that gut hormones are more likely to mediate reduced appetite and food intake after RYGB. 24 As most of our subjects were unlikely to have achieved their nadir weight at 1 year, it may be too early to detect significant correlations between levels of L-cell peptides and ultimate response to surgery.
Although it is generally accepted that fasting ghrelin levels increase after weight loss induced by a calorie-restricted diet 9 changes in ghrelin after bariatric surgery are more varied. As in this report, most studies have shown an increase in ghrelin after LAGB, however, results from prospective studies of RYGB are particularly inconsistent. 12 The increase in fasting ghrelin after LAGB seems to occur over time indicating that such change is related to weight loss as opposed to restriction of nutrient flow. In contrast, the relative decrease in fasting ghrelin after RYGB occurs as early as 2-6 weeks after surgery as also reported by Morinigo et al. 25 suggesting that the decrease in ghrelin is mostly a result of altered anatomy. 26 In this study, we have found that after RYGB there was inter-individual variation in ghrelin levels over time: fasting and AUC ghrelin remained the same Hormone changes after bariatric surgery J Korner et al or decreased in most individuals, yet approximately onefourth of subjects exhibited an increase that was not dependent on weight loss or change in insulin levels. It is possible that variable treatment of vagal fibers explains interindividual variation in fasting ghrelin levels. 27 Homeostasis model of assessment decreased to a greater extent in RYGB subjects and did not correlate with the degree of weight loss as was observed in LAGB subjects. In a large prospective study by Lee et al., 28 similar reductions in HOMA-IR were observed in LAGB and RYGB subjects at equivalent amounts of weight loss, however, it was not reported if changes in HOMA-IR correlated statistically with weight reduction; it is, therefore, unclear if the improvement in insulin resistance was driven mainly by weight reduction in both procedures. As suggested from human and animal studies, neurohormonal modulators of insulin sensitivity affected by bypass of the proximal intestine, and/or early enhanced nutrient delivery more distally, may play a more prominent role in mediating the beneficial effects on glucose homeostasis after bypass, 6 whereas, weight loss is likely to be the predominant factor inducing remission of diabetes after gastric banding. 29 Increased GLP-1 and PYY levels together with an absence of a compensatory rise in ghrelin in most RYGB patients would be expected to favor improved insulin sensitivity as these hormone affect glucose homeostasis in addition to appetitive behavior. 8, [30] [31] [32] After diet-induced weight loss reductions in bioactive thyroid hormones and sympathetic nervous system tone, and a reduction in energy expenditure beyond that predicted by the loss of body mass have been observed. 33, 34 These changes are believed to be an adaptive response to protect an organism from semi-starvation that is mediated in part by the decline in circulating leptin concentrations. Restoration of leptin concentrations to levels measured before calorie restriction normalizes some of these neuroendocrine changes. 34, 35 Similarly, after RYGB resting energy expenditure is also lower than that expected for the reduction in fatfree mass. 36, 37 We have shown that after RYGB, there was a profound decrease in leptin levels and a decrease in free T 3 without a sufficient compensatory rise in thyrotropic hormone. This pattern mimics a euthyroid sick syndrome observed in low leptin states such as anorexia nervosa. 38 Leptin regulates the thyroid axis at multiple levels, 39 however, the correlation coefficients relating the percentage change in free T 3 with the percentage change in leptin did not reach statistical significance in either surgical group. It is possible that more subjects would be required to show an interaction with free T 3 and leptin in this setting. Furthermore, measurement of peripheral levels may not accurately reflect leptin levels reaching thyrotropin-releasing hormone neurons with the central nervous system. Other metabolic factors, in addition to possible changes in peripheral deiodinase activity, may have also contributed to the decrease in T 3 after RYGB. For example, thyrotropin-releasing hormone neurons are regulated by the hypothalamic melanocortin system, 39 which in turn, is regulated by both insulin and leptin. 40, 41 Thus, leptin insufficiency together with decreased insulin levels may act in conjunction to suppress melanocortin tone and limit weight loss through a reduction in T3 levels and energy expenditure.
The decrease in leptin levels at 1 year was proportional to the degree of weight loss after both procedures. A limitation of this study is that body composition analysis was not performed. However, our findings from a cross-sectional study using whole body MRI (magnetic resonance imaging) in which we have shown that plasma leptin levels adjusted for total adipose tissue and weight loss were similar in weight stable individuals at a mean of 2 years after LAGB and RYGB 42 suggesting that the regulation of leptin secretion does not differ between procedures. Although the majority of circulating leptin is produced in fat cells, leptin is also secreted into the systemic circulation from endocrine cells present in the gastric mucosa. 43 However, it is unlikely that the early decline in leptin levels after RYGB was because of bypassing the stomach as changes in circulating leptin concentrations have not been detected in the early postoperative period after gastrectomy. 26 Certainly, there are variables that play critical roles in weight loss such as physical activity and eating patterns, together with environmental and psychological factors that were not addressed in this study. As an observational study, we are only able to draw inferences regarding the physiological effects that result from the hormonal changes described, but these observations form a foundation from which one may proceed with interventional studies in animals and humans. Although bariatric surgery is usually quite effective, weight loss is less than optimal in some individuals and significant weight regain may occur in others after having achieved a satisfactory plateau. In such individuals, a combination of lifestyle modifications, surgery and pharmacotherapy may be necessary to maximize results, particularly as new reagents are likely to become available in the future. In theory, one might consider GLP-1 or PYY analogs, or ghrelin antagonists after LAGB, or replacement dose of leptin after RYGB in individuals for whom leptin insufficiency may be limiting further weight reduction. There may be a myriad of other possibilities to optimize non-surgical and surgical treatments for obesity as more gut hormones are studied and as the drug pipeline begins to catch up with our growing understanding of energy homeostasis.
